<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00683735</url>
  </required_header>
  <id_info>
    <org_study_id>DZBL 2008-Nauck-01</org_study_id>
    <secondary_id>EudraCT: 2008-001663-11</secondary_id>
    <nct_id>NCT00683735</nct_id>
  </id_info>
  <brief_title>Quantification of the Dipeptidyl Peptidase (DPP)-4 Inhibition-mediated Enhancement of the Activity of the Entero-insular Axis</brief_title>
  <official_title>Quantification of the DPP-4 Inhibition-mediated Enhancement of the Activity of the Entero-insular Axis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michael A. Nauck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Diabeteszentrum Bad Lauterberg im Harz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: To assess the effect if co-administration of sitagliptin and metformin compared to&#xD;
      placebo on the incretin effect (based on the comparison of the insulin secretory response to&#xD;
      oral glucose load and an 'isoglycaemic' intravenous glucose load). Hypothesis: Treatment with&#xD;
      co-administration of sitagliptin and metformin provides a greater incretin effect compared to&#xD;
      placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A new class of antidiabetic agents, the DPP-4 inhibitors, are thought to protect endogenously&#xD;
      secreted incretin hormones (e.g., GLP-1 and GIP) from proteolytic degradation and&#xD;
      inactivation. Since GLP-1 has antidiabetogenic properties, an augmentation of meal-related&#xD;
      responses of intact, biologically active GLP-1 can be expected to increase the impact of&#xD;
      incretin stimulation to insulin secretory responses. The incretin effect in type 2 diabetic&#xD;
      patients is reduced due to an impaired secretion of GLP-1 and a reduced insulinotropic&#xD;
      effectiveness of GIP. Therefore, sitagliptin (DPP-4 inhibitor) will be studied in 20 type&#xD;
      2-diabetic patients, who will be treated sequentially (crossover design) with (a) placebo,&#xD;
      (b) metformin alone, (c) Sitagliptin alone, and (d) a combination of metformin and&#xD;
      Sitagliptin for periods of 6 days (with a washout period of 3 days between treatment. The&#xD;
      insulin secretory response (insulin, C-peptide, insulin secretion rates determined by&#xD;
      deconvolution analysis) will be compared between experiments with oral glucose (75 g) and&#xD;
      &quot;isoglycaemic&quot; intravenous glucose infusions (20% glucose i.v.). The difference represents&#xD;
      the &quot;incretin effect&quot;. It is expected that the incretin effect in type 2-diabetic patients&#xD;
      will be enhanced with sitagliptin treatment, especially combined with metformin.&#xD;
&#xD;
      A secondary objective is to relate the potential increase in the % incretin contribution to&#xD;
      insulin secretory response after oral glucose (incretin effect) to changes in the oral&#xD;
      glucose-induced response of intact GLP-1 and GIP (measured by specific RIAs). Thus, it will&#xD;
      be established, to which degree sitagliptin acts as an &quot;incretin enhancer&quot; in type 2 diabetic&#xD;
      patients.&#xD;
&#xD;
      This study will also determine how the combination of sitagliptin to metformin affects the&#xD;
      incretin response and insulin secretory response. Metformin is a standard and widely used&#xD;
      antihyperglycemic agent which lowers glycemic levels primarily through suppression of hepatic&#xD;
      glucose output and improvement in peripheral insulin resistance, resulting in increased&#xD;
      glucose transport and utilization by skeletal muscle. There are data to suggest that&#xD;
      metformin increases endogenous GLP-1 levels in response to an oral glucose load in obese&#xD;
      humans (1).&#xD;
&#xD;
      Therefore it is of relevance to confirm this novel activity of metformin in patients with&#xD;
      type 2 diabetes, and to assess potential functional consequences regarding the incretin&#xD;
      effect.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the effect of co-administration of sitagliptin and metformin compared to placebo on the incretin effect (based on the comparison of the insulin secretory response to oral glucose load and an 'isoglycaemic' intravenous glucose load)</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the effect of sitagliptin compared with placebo on the incretin effect (based on the comparison of the insulin secretory response to oral glucose load and an 'isoglycaemic' intravenous glucose load)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sitagliptin and placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>placebo and metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sitagliptin and metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>100 mg once daily in the morning</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>up to 2000 mg/day</description>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>500mg 1-0-0-0</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>100mg 1-0-0-0</description>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 2-diabetes mellitus&#xD;
&#xD;
          -  BMI 25-35 kg/m2&#xD;
&#xD;
          -  HbA1c 6.5%-9% (without OHA medication)&#xD;
&#xD;
          -  HbA1c 6%-8.5% (OHA monotherapy with metformin or sulfonylurea)&#xD;
&#xD;
          -  Patient understands the study-procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1-diabetes mellitus&#xD;
&#xD;
          -  C-peptide &lt; 0.7ng/mL (0.23 nmol/L)&#xD;
&#xD;
          -  Patient has been taking oral anti-hyperglycemic agent (OHA) within the prior 12 weeks,&#xD;
             except metformin or a sulfonylurea&#xD;
&#xD;
          -  Patient has required insulin therapy within the past 12 weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael A. Nauck, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diabeteszentrum Bad Lauterberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diabeteszentrum Bad Lauterberg</name>
      <address>
        <city>Bad Lauterberg</city>
        <zip>37431</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>May 21, 2008</study_first_submitted>
  <study_first_submitted_qc>May 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2008</study_first_posted>
  <last_update_submitted>December 17, 2015</last_update_submitted>
  <last_update_submitted_qc>December 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Diabeteszentrum Bad Lauterberg im Harz</investigator_affiliation>
    <investigator_full_name>Michael A. Nauck</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>Incretin, DPP-4, metformin, sitagliptin, insulin secretion</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

